SynthesisFrontiers in medicine2026
Efficacy of liposome bupivacaine in transversus abdominis plane blocks for postoperative analgesia: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This meta-analysis evaluates the efficacy of liposomal bupivacaine (LB) versus standard bupivacaine (SB), with or without adjuvants, in transversus abdominis plane (TAP) blocks for postoperative analgesia. Methods: Registered in PROSPERO (CRD420251084761), this meta-analysis screened randomized controlled trials (RCTs) published from 2000 to 2025 in PubMed, the Cochrane Library, Embase, and Wanfang databases. The primary outcome was the cumulative morphine milligram equivalent (MME) within 1 day after surgery. Secondary outcomes included the MME within 2-3 days after surgery, pain scores on postoperative days 1-3, time to first rescue analgesia, time to first flatus passage, time to first ambulation, postoperative nausea and vomiting (PONV), local anesthetic-related adverse events and toxicity, and length of hospital stay. Results: A total of 13 randomized controlled trials (RCTs) ( Conclusion: Liposomal bupivacaine used in TAP blocks can provide only minimal reductions in opioid consumption and pain relief after surgery compared to standard bupivacaine. Given that the quality of evidence was low to very low, large-scale RCTs are required to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.